| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.74 [0.63, 0.87] | | < 1 | | 64% | 8 studies (8/-) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.62 [0.55, 0.70] | | < 1 | | 21% | 4 studies (4/-) | 100.0 % | low | not evaluable | high | important | - |
| MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.51 [0.43, 0.61] | | < 1 | | 67% | 5 studies (5/-) | 100.0 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.56 [0.46, 0.69] | | < 1 | | 66% | 6 studies (6/-) | 100.0 % | low | not evaluable | high | important | - |
| RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.65 [0.51, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| DCR | 1.19 [0.86, 1.63] | | > 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 3.12 [1.57, 6.17] | | > 1 | | 92% | 7 studies (7/-) | 99.9 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 5.68 [3.20, 10.11] | | > 1 | | 75% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.91 [0.24, 3.51] | | < 1 | | 66% | 2 studies (2/-) | 55.4 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.52 [0.15, 1.81] | | < 1 | | 96% | 2 studies (2/-) | 84.8 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.15 [0.10, 0.21] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.11 [0.07, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.29 [0.76, 2.21] | | < 1 | | 90% | 8 studies (8/-) | 17.2 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.19 [0.54, 2.61] | | < 1 | | 97% | 8 studies (8/-) | 33.3 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.21 [0.38, 3.91] | | < 1 | | 0% | 6 studies (6/-) | 37.3 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.13 [0.41, 3.10] | | < 1 | | 97% | 7 studies (7/-) | 40.8 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.00 [0.30, 3.37] | | < 1 | | 96% | 7 studies (7/-) | 50.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.45 [0.12, 1.68] | | < 1 | | 0% | 6 studies (6/-) | 88.1 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.13 [0.42, 3.01] | | < 1 | | 4% | 6 studies (6/-) | 40.3 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 1.16 [0.16, 8.29] | | < 1 | | 0% | 2 studies (2/-) | 44.1 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.05 [0.27, 4.00] | | < 1 | | 0% | 6 studies (6/-) | 47.2 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.38 [0.13, 1.09] | | < 1 | | 0% | 6 studies (6/-) | 96.3 % | low | not evaluable | high | non important | - |
| Chills TRAE (grade 3-4) | 0.75 [0.08, 7.20] | | < 1 | | 0% | 3 studies (3/-) | 59.9 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.62 [0.28, 1.37] | | < 1 | | 80% | 7 studies (7/-) | 87.9 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.94 [0.11, 8.13] | | < 1 | | 0% | 3 studies (3/-) | 52.1 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 1.56 [0.25, 9.72] | | < 1 | | 0% | 4 studies (4/-) | 31.8 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.42 [0.34, 5.93] | | < 1 | | 0% | 5 studies (5/-) | 31.7 % | low | serious | high | non important | - |
| Diabetes TRAE (grade 3-4) | 1.93 [0.17, 21.31] | | < 1 | | 0% | 2 studies (2/-) | 29.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.73 [0.38, 1.40] | | < 1 | | 79% | 8 studies (8/-) | 82.8 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.32 [0.62, 2.79] | | < 1 | | 0% | 4 studies (4/-) | 23.5 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.78 [0.45, 7.09] | | < 1 | | 0% | 5 studies (5/-) | 20.7 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.96 [0.24, 3.80] | | < 1 | | 72% | 3 studies (3/-) | 52.2 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.25 [0.51, 3.02] | | < 1 | | 34% | 6 studies (6/-) | 31.3 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.73 [0.18, 3.06] | | < 1 | | 94% | 4 studies (4/-) | 66.5 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.64 [0.20, 2.07] | | < 1 | | 0% | 6 studies (6/-) | 77.4 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.90 [1.14, 7.34] | | < 1 | | 0% | 7 studies (7/-) | 1.3 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.48 [0.06, 34.16] | | < 1 | | 84% | 3 studies (3/-) | 40.5 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 3.72 [0.39, 35.19] | | < 1 | | 0% | 2 studies (2/-) | 12.8 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.03 [0.27, 4.02] | | < 1 | | 0% | 6 studies (6/-) | 48.0 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.58 [0.31, 1.08] | | < 1 | | 12% | 8 studies (8/-) | 95.6 % | low | serious | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.96 [0.29, 3.12] | | < 1 | | 0% | 8 studies (8/-) | 52.9 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.31 [0.31, 5.56] | | < 1 | | 73% | 8 studies (8/-) | 35.6 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.32 [0.36, 4.77] | | < 1 | | 79% | 8 studies (8/-) | 33.8 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.09 [1.14, 3.84] | | < 1 | | 19% | 4 studies (4/-) | 0.9 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.25 [0.38, 4.09] | | < 1 | | 22% | 7 studies (7/-) | 35.6 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 0.99 [0.22, 4.36] | | < 1 | | 0% | 5 studies (5/-) | 50.6 % | low | not evaluable | high | non important | - |
| Myositis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 1.45 [0.49, 4.30] | | < 1 | | 0% | 6 studies (6/-) | 25.0 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.57 [0.52, 4.72] | | < 1 | | 0% | 6 studies (6/-) | 21.2 % | low | not evaluable | high | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.75 [0.16, 3.57] | | < 1 | | 0% | 6 studies (6/-) | 64.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.08 [0.40, 2.89] | | < 1 | | 0% | 8 studies (8/-) | 43.9 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.04 [0.29, 3.78] | | < 1 | | 0% | 6 studies (6/-) | 47.5 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.03 [0.46, 2.33] | | < 1 | | 33% | 8 studies (8/-) | 46.9 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 0.99 [0.08, 12.98] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.17 [0.13, 10.40] | | < 1 | | 49% | 3 studies (3/-) | 44.6 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.03 [0.23, 4.70] | | < 1 | | 77% | 4 studies (4/-) | 48.3 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.65 [0.21, 12.78] | | < 1 | | 0% | 3 studies (3/-) | 31.7 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.82 [0.12, 5.39] | | < 1 | | 0% | 4 studies (4/-) | 58.3 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 2.28 [0.62, 8.34] | | < 1 | | 0% | 5 studies (5/-) | 10.7 % | low | serious | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.48 [0.09, 2.61] | | < 1 | | 0% | 4 studies (4/-) | 80.2 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.03 [0.21, 5.19] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.95 [0.30, 3.03] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.34 [0.07, 1.70] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.69 [0.02, 20.65] | | < 1 | | 0% | 1 study (1/-) | 58.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.03 [0.21, 5.19] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.83 [0.34, 2.05] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.96 [0.34, 2.73] | | < 1 | | 0% | 1 study (1/-) | 52.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.71 [0.31, 1.62] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.45 [0.10, 2.06] | | < 1 | | 0% | 1 study (1/-) | 84.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.68 [0.17, 2.78] | | < 1 | | 0% | 1 study (1/-) | 70.2 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.38 [0.06, 30.82] | | < 1 | | 0% | 1 study (1/-) | 42.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.80 [0.20, 3.14] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
